{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:48:20Z","timestamp":1776829700270,"version":"3.51.2"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["WWCR 24-0426"],"award-info":[{"award-number":["WWCR 24-0426"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Ministry of Education and Science | Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MEC-ONC\/4606\/2021"],"award-info":[{"award-number":["PTDC\/MEC-ONC\/4606\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","award":["FKC\/ATG4TALL\/2023"],"award-info":[{"award-number":["FKC\/ATG4TALL\/2023"]}],"id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","award":["FKC\/ATG4TALL\/2023"],"award-info":[{"award-number":["FKC\/ATG4TALL\/2023"]}],"id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","award":["FKC\/ATG4TALL\/2023"],"award-info":[{"award-number":["FKC\/ATG4TALL\/2023"]}],"id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","award":["FKC\/ATG4TALL\/2023"],"award-info":[{"award-number":["FKC\/ATG4TALL\/2023"]}],"id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","award":["FKC\/ATG4TALL\/2023"],"award-info":[{"award-number":["FKC\/ATG4TALL\/2023"]}],"id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","award":["FKC\/ATG4TALL\/2023"],"award-info":[{"award-number":["FKC\/ATG4TALL\/2023"]}],"id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","award":["FKC\/ATG4TALL\/2023"],"award-info":[{"award-number":["FKC\/ATG4TALL\/2023"]}],"id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41375-025-02723-2","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T06:54:19Z","timestamp":1755154459000},"page":"2575-2589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"39","author":[{"given":"Patr\u00edcia","family":"Amaral","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7240-4123","authenticated-orcid":false,"given":"Rhona","family":"Christie","sequence":"additional","affiliation":[]},{"given":"Daisy O. F.","family":"Gresham","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1043-2631","authenticated-orcid":false,"given":"Emma J. M.","family":"Lucas","sequence":"additional","affiliation":[]},{"given":"Luyao Kevin","family":"Xu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3255-7504","authenticated-orcid":false,"given":"Lena","family":"Behrmann","sequence":"additional","affiliation":[]},{"given":"Jonathan","family":"Bond","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2783-0712","authenticated-orcid":false,"given":"Sofie","family":"Degerman","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-3720","authenticated-orcid":false,"given":"Frederik W.","family":"van Delft","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-8570","authenticated-orcid":false,"given":"Steven","family":"Goossens","sequence":"additional","affiliation":[]},{"given":"Melanie","family":"Hagleitner","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-5246","authenticated-orcid":false,"given":"Chris","family":"Halsey","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-5117","authenticated-orcid":false,"given":"Nicholas","family":"Jones","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-4027","authenticated-orcid":false,"given":"Tim","family":"Lammens","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1107-6513","authenticated-orcid":false,"given":"Frank N.","family":"van Leeuwen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6835-3791","authenticated-orcid":false,"given":"Marc R.","family":"Mansour","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-8954","authenticated-orcid":false,"given":"Panagiotis","family":"Ntziachristos","sequence":"additional","affiliation":[]},{"given":"David","family":"O\u2019Connor","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4826-8976","authenticated-orcid":false,"given":"Jo\u00e3o T.","family":"Barata","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2723_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1200\/JCO.2016.69.6278","volume":"35","author":"D O\u2019Connor","year":"2017","unstructured":"O\u2019Connor D, Moorman AV, Wade R, Hancock J, Tan RM, Bartram J, et al. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017;35:660\u20137.","journal-title":"J Clin Oncol"},{"key":"2723_CR2","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1200\/JCO.22.02734","volume":"41","author":"D O\u2019Connor","year":"2023","unstructured":"O\u2019Connor D, Demeulemeester J, Conde L, Kirkwood A, Fung K, Papaleonidopoulou F, et al. The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023;41:3545\u201356.","journal-title":"J Clin Oncol"},{"key":"2723_CR3","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1200\/JCO.23.00088","volume":"41","author":"EA Raetz","year":"2023","unstructured":"Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, et al. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. J Clin Oncol. 2023;41:5025\u201334.","journal-title":"J Clin Oncol"},{"key":"2723_CR4","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","volume":"38","author":"SR Rheingold","year":"2024","unstructured":"Rheingold SR, Bhojwani D, Ji L, Xu X, Devidas M, Kairalla JA, et al. Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia. 2024;38:2382\u201394.","journal-title":"Leukemia"},{"key":"2723_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325:833\u201342.","journal-title":"JAMA"},{"key":"2723_CR6","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","volume":"26","author":"EA Raetz","year":"2008","unstructured":"Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children\u2019s Oncology Group Study[corrected]. J Clin Oncol. 2008;26:3971\u20138.","journal-title":"J Clin Oncol"},{"key":"2723_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29901","volume":"69","author":"JA Whitlock","year":"2022","unstructured":"Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer. 2022;69:e29901.","journal-title":"Pediatr Blood Cancer"},{"key":"2723_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.15919","volume":"186","author":"TM Horton","year":"2019","unstructured":"Horton TM, Whitlock JA, Lu X, O\u2019Brien MM, Borowitz MJ, Devidas M, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group. Br J Haematol. 2019;186:274\u201385.","journal-title":"Br J Haematol"},{"key":"2723_CR9","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1200\/JCO.21.02678","volume":"40","author":"DT Teachey","year":"2022","unstructured":"Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, et al. Children\u2019s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022;40:2106\u201318.","journal-title":"J Clin Oncol"},{"key":"2723_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021;2:284\u201399.","journal-title":"Nat Cancer"},{"key":"2723_CR11","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021;11:1440\u201353.","journal-title":"Cancer Discov"},{"key":"2723_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3324\/haematol.2023.284353","volume":"110","author":"J Ravikrishnan","year":"2025","unstructured":"Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, et al. LP-118 is a novel B-cell lymphoma 2 \/ extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica. 2025;110:78\u201391.","journal-title":"Haematologica"},{"key":"2723_CR13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1126\/science.1259037","volume":"346","author":"MR Mansour","year":"2014","unstructured":"Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014;346:1373\u20137.","journal-title":"Science"},{"key":"2723_CR14","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1182\/blood-2016-09-742148","volume":"129","author":"S Rahman","year":"2017","unstructured":"Rahman S, Magnussen M, Le\u00f3n TE, Farah N, Li Z, Abraham BJ, et al. Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood. 2017;129:3221\u20136.","journal-title":"Blood"},{"key":"2723_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood.2023021906","volume":"143","author":"D O\u2019Connor","year":"2024","unstructured":"O\u2019Connor D, Valle-Incl\u00e1n JE, Conde L, Bloye G, Rahman S, Costa JR, et al. Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL. Blood. 2024;143:933\u20137.","journal-title":"Blood"},{"key":"2723_CR16","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","volume":"632","author":"P P\u00f6l\u00f6nen","year":"2024","unstructured":"P\u00f6l\u00f6nen P, Di Giacomo D, Seffernick AE, Elsayed A, Kimura S, Benini F, et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature. 2024;632:1082\u201391.","journal-title":"Nature"},{"key":"2723_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157\u201363.","journal-title":"Nature"},{"key":"2723_CR18","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","volume":"35","author":"J Bond","year":"2017","unstructured":"Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, et al. Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. J Clin Oncol. 2017;35:2683\u201391.","journal-title":"J Clin Oncol"},{"key":"2723_CR19","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2018.197848","volume":"104","author":"J Bond","year":"2019","unstructured":"Bond J, Touzart A, Lepr\u00eatre S, Graux C, Bargetzi M, Lhermitte L, et al. DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica. 2019;104:1617\u201325.","journal-title":"Haematologica"},{"key":"2723_CR20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood-2023-177781","volume":"142","author":"CS Tremblay","year":"2023","unstructured":"Tremblay CS, Saw J, Boyle JA, Haigh K, Litalien V, McCalmont H, et al. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia. Blood. 2023;142:274\u201389.","journal-title":"Blood"},{"key":"2723_CR21","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1084\/jem.20180570","volume":"215","author":"IM Ari\u00ebs","year":"2018","unstructured":"Ari\u00ebs IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, et al. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018;215:3094\u2013114.","journal-title":"J Exp Med"},{"key":"2723_CR22","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1158\/1078-0432.CCR-23-0415","volume":"29","author":"C Saygin","year":"2023","unstructured":"Saygin C, Giordano G, Shimamoto K, Eisfelder B, Thomas-Toth A, Venkataraman G, et al. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023;29:3151\u201361.","journal-title":"Clin Cancer Res"},{"key":"2723_CR23","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/leu.2016.60","volume":"30","author":"K Matlawska-Wasowska","year":"2016","unstructured":"Matlawska-Wasowska K, Kang H, Devidas M, Wen J, Harvey RC, Nickl CK, et al. MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study. Leukemia. 2016;30:1909\u201312.","journal-title":"Leukemia"},{"key":"2723_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3324\/haematol.2015.141218","volume":"101","author":"J Bond","year":"2016","unstructured":"Bond J, Marchand T, Touzart A, Cieslak A, Trinquand A, Sutton L, et al. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for research in adult acute lymphoblastic leukemia study. Haematologica. 2016;101:732\u201340.","journal-title":"Haematologica"},{"key":"2723_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147\u201356.","journal-title":"Lancet Oncol"},{"key":"2723_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adr2012","volume":"17","author":"M Gower","year":"2025","unstructured":"Gower M, Li X, Aguilar-Navarro AG, Lin B, Fernandez M, Edun G, et al. An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup. Sci Transl Med. 2025;17:eadr2012.","journal-title":"Sci Transl Med"},{"key":"2723_CR27","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.3324\/haematol.2017.185801","volume":"103","author":"N Farah","year":"2018","unstructured":"Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, et al. Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial. Haematologica. 2018;103:e288\u2013e92.","journal-title":"Haematologica"},{"key":"2723_CR28","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood.2023023754","volume":"144","author":"M Simonin","year":"2024","unstructured":"Simonin M, Vasseur L, Lenglin\u00e9 E, Lhermitte L, Cabannes-Hamy A, Balsat M, et al. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients. Blood. 2024;144:1570\u201380.","journal-title":"Blood"},{"key":"2723_CR29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211\u20138.","journal-title":"Nat Genet"},{"key":"2723_CR30","doi-asserted-by":"crossref","unstructured":"Hughes AD, P\u00f6l\u00f6nen P, Teachey DT. Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma. Haematologica. 2025; Epub ahead of print.","DOI":"10.3324\/haematol.2024.285643"},{"key":"2723_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45796-w","volume":"15","author":"J Ma","year":"2024","unstructured":"Ma J, Li L, Ma B, Liu T, Wang Z, Ye Q, et al. MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation. Nat Commun. 2024;15:1871.","journal-title":"Nat Commun"},{"key":"2723_CR32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda E, Beaulieu ME, Moreno V, Casacuberta-Serra S, Mart\u00ednez-Mart\u00edn S, Foradada L, et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med. 2024;30:762\u201371.","journal-title":"Nat Med"},{"key":"2723_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103756","volume":"75","author":"V Llombart","year":"2022","unstructured":"Llombart V, Mansour MR. Therapeutic targeting of \u201cundruggable\u201d MYC. EBioMedicine. 2022;75:103756.","journal-title":"EBioMedicine"},{"key":"2723_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm.3078","volume":"19","author":"G Tzoneva","year":"2013","unstructured":"Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med. 2013;19:368\u201371.","journal-title":"Nat Med"},{"key":"2723_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.2019002220","volume":"135","author":"B Li","year":"2020","unstructured":"Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135:41\u201355.","journal-title":"Blood"},{"key":"2723_CR36","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/ijc.34819","volume":"154","author":"Y Walia","year":"2024","unstructured":"Walia Y, de Bock CE, Huang Y. The landscape of alterations affecting epigenetic regulators in T-cell acute lymphoblastic leukemia: Roles in leukemogenesis and therapeutic opportunities. Int J Cancer. 2024;154:1522\u201336.","journal-title":"Int J Cancer"},{"key":"2723_CR37","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3324\/haematol.2019.223677","volume":"105","author":"A Touzart","year":"2020","unstructured":"Touzart A, Boissel N, Belhocine M, Smith C, Graux C, Latiri M, et al. Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. Haematologica. 2020;105:1575\u201381.","journal-title":"Haematologica"},{"key":"2723_CR38","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/pbc.25958","volume":"63","author":"M Borss\u00e9n","year":"2016","unstructured":"Borss\u00e9n M, Haider Z, Landfors M, Nor\u00e9n-Nystr\u00f6m U, Schmiegelow K, \u00c5sberg AE, et al. DNA methylation adds prognostic value to minimal residual disease status in Pediatric T-Cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:1185\u201392.","journal-title":"Pediatr Blood Cancer"},{"key":"2723_CR39","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s43018-022-00370-5","volume":"3","author":"S Hetzel","year":"2022","unstructured":"Hetzel S, Mattei AL, Kretzmer H, Qu C, Chen X, Fan Y, et al. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022;3:768\u201382.","journal-title":"Nat Cancer"},{"key":"2723_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2643-3230.BCD-20-0059","volume":"1","author":"J Roels","year":"2020","unstructured":"Roels J, Th\u00e9noz M, Szarzy\u0144ska B, Landfors M, De Coninck S, Demoen L, et al. Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia. Blood Cancer Discov. 2020;1:274\u201389.","journal-title":"Blood Cancer Discov"},{"key":"2723_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cam4.1917","volume":"8","author":"Z Haider","year":"2019","unstructured":"Haider Z, Larsson P, Landfors M, K\u00f6hn L, Schmiegelow K, Flaegstad T, et al. An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression. Cancer Med. 2019;8:311\u201324.","journal-title":"Cancer Med"},{"key":"2723_CR42","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer Hackenhaar F, Refhagen N, Hagleitner MM, van Leeuwen FN, Marquart HV, Madsen HO, et al. CpG island methylator phenotype classification improves risk assessment in pediatric T-cell Acute Lymphoblastic Leukemia. Blood. 2025;145:2161\u201378.","DOI":"10.1182\/blood.2024026027"},{"key":"2723_CR43","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00277-022-04912-w","volume":"101","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Dai Y, Tang X. Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed\/refractory T-cell acute lymphoblastic leukaemia. Ann Hematol. 2022;101:2525\u20138.","journal-title":"Ann Hematol"},{"key":"2723_CR44","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, Li Y, May WS, Adams CB. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. Hematol Oncol Stem Cell Ther. 2021;14:246\u201351.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2723_CR45","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2:1002\u201317.","journal-title":"Nat Cancer"},{"key":"2723_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-022-01736-1","volume":"9","author":"L Provez","year":"2022","unstructured":"Provez L, Van Puyvelde B, Corveleyn L, Demeulemeester N, Verhelst S, Lintermans B, et al. An interactive mass spectrometry atlas of histone posttranslational modifications in T-cell acute leukemia. Sci Data. 2022;9:626.","journal-title":"Sci Data"},{"key":"2723_CR47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.2651","volume":"18","author":"P Ntziachristos","year":"2012","unstructured":"Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012;18:298\u2013301.","journal-title":"Nat Med"},{"key":"2723_CR48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature09727","volume":"471","author":"CG Mullighan","year":"2011","unstructured":"Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235\u20139.","journal-title":"Nature"},{"key":"2723_CR49","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2016-06-721191","volume":"129","author":"S Goossens","year":"2017","unstructured":"Goossens S, Peirs S, Van Loocke W, Wang J, Takawy M, Matthijssens F, et al. Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia. Blood. 2017;129:981\u201390.","journal-title":"Blood"},{"key":"2723_CR50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/leu.2017.282","volume":"32","author":"M Waibel","year":"2018","unstructured":"Waibel M, Vervoort SJ, Kong IY, Heinzel S, Ramsbottom KM, Martin BP, et al. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. Leukemia. 2018;32:237\u201341.","journal-title":"Leukemia"},{"key":"2723_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024;627:221\u20138.","journal-title":"Nature"},{"key":"2723_CR52","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ng.2508","volume":"45","author":"K De Keersmaecker","year":"2013","unstructured":"De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet. 2013;45:186\u201390.","journal-title":"Nat Genet"},{"key":"2723_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0168-9","volume":"7","author":"H Dvinge","year":"2015","unstructured":"Dvinge H, Bradley RK. Widespread intron retention diversifies most cancer transcriptomes. Genome Med. 2015;7:45.","journal-title":"Genome Med"},{"key":"2723_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj8357","volume":"8","author":"C Han","year":"2022","unstructured":"Han C, Khodadadi-Jamayran A, Lorch AH, Jin Q, Serafin V, Zhu P, et al. SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia. Sci Adv. 2022;8:eabj8357.","journal-title":"Sci Adv"},{"key":"2723_CR55","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ccell.2020.01.001","volume":"37","author":"J Jiang","year":"2020","unstructured":"Jiang J, Wang J, Yue M, Cai X, Wang T, Wu C, et al. Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis. Cancer Cell. 2020;37:200\u201315.e5.","journal-title":"Cancer Cell"},{"key":"2723_CR56","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/cncr.31398","volume":"124","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018;124:2758\u201365.","journal-title":"Cancer"},{"key":"2723_CR57","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","volume":"37","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, Stahl M, Taylor J, Mi X, Chandhok NS, Watts J, et al. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 2023;37:2512\u20136.","journal-title":"Leukemia"},{"key":"2723_CR58","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13046-024-03130-8","volume":"43","author":"T Ji","year":"2024","unstructured":"Ji T, Yang Y, Yu J, Yin H, Chu X, Yang P, et al. Targeting RBM39 through indisulam induced mis-splicing of mRNA to exert anti-cancer effects in T-cell acute lymphoblastic leukemia. J Exp Clin Cancer Res. 2024;43:205.","journal-title":"J Exp Clin Cancer Res"},{"key":"2723_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201724","volume":"10","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Ji M, Xia Y, Han X, Li M, Li W, et al. Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T-Cell Acute Lymphoblastic Leukemia. Adv Sci. 2023;10:e2201724.","journal-title":"Adv Sci"},{"key":"2723_CR60","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1038\/s41375-022-01651-9","volume":"36","author":"P Feng","year":"2022","unstructured":"Feng P, Chen D, Wang X, Li Y, Li Z, Li B, et al. Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia. Leukemia. 2022;36:2180\u20138.","journal-title":"Leukemia"},{"key":"2723_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113704","volume":"43","author":"M Rivera","year":"2024","unstructured":"Rivera M, Zhang H, Pham J, Isquith J, Zhou QJ, Balaian L, et al. Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Cell Rep. 2024;43:113704.","journal-title":"Cell Rep"},{"key":"2723_CR62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426742122","volume":"122","author":"K Bertulfo","year":"2025","unstructured":"Bertulfo K, Perez-Duran P, Miller H, Ma C, Ambesi-Impiombato A, Samon J, et al. Therapeutic targeting of the NOTCH1 and neddylation pathways in T cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2025;122:e2426742122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2723_CR63","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1182\/blood-2017-05-784603","volume":"130","author":"V Serafin","year":"2017","unstructured":"Serafin V, Capuzzo G, Milani G, Minuzzo SA, Pinazza M, Bortolozzi R, et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood. 2017;130:2750\u201361.","journal-title":"Blood"},{"key":"2723_CR64","first-page":"1056","volume":"106","author":"Y Shi","year":"2021","unstructured":"Shi Y, Beckett MC, Blair HJ, Tirtakusuma R, Nakjang S, Enshaei A, et al. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica. 2021;106:1056\u201366.","journal-title":"Haematologica"},{"key":"2723_CR65","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129:e26\u2013e37.","journal-title":"Blood"},{"key":"2723_CR66","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2021015106","volume":"140","author":"S Laukkanen","year":"2022","unstructured":"Laukkanen S, Veloso A, Yan C, Oksa L, Alpert EJ, Do D, et al. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood. 2022;140:1891\u2013906.","journal-title":"Blood"},{"key":"2723_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo5228","volume":"14","author":"J Hu","year":"2022","unstructured":"Hu J, Jarusiewicz J, Du G, Nishiguchi G, Yoshimura S, Panetta JC, et al. Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia. Sci Transl Med. 2022;14:eabo5228.","journal-title":"Sci Transl Med"},{"key":"2723_CR68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3324\/haematol.2013.088674","volume":"99","author":"K De Keersmaecker","year":"2014","unstructured":"De Keersmaecker K, Porcu M, Cox L, Girardi T, Vandepoel R, de Beeck JO, et al. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica. 2014;99:85\u201393.","journal-title":"Haematologica"},{"key":"2723_CR69","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjh.17093","volume":"191","author":"AV Moorman","year":"2020","unstructured":"Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, et al. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. Br J Haematol. 2020;191:844\u201351.","journal-title":"Br J Haematol"},{"key":"2723_CR70","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","volume":"124","author":"J Irving","year":"2014","unstructured":"Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124:3420\u201330.","journal-title":"Blood"},{"key":"2723_CR71","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3324\/haematol.2017.185975","volume":"104","author":"EC Matheson","year":"2019","unstructured":"Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, et al. Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. Haematologica. 2019;104:1804\u201311.","journal-title":"Haematologica"},{"key":"2723_CR72","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/ng.924","volume":"43","author":"PP Zenatti","year":"2011","unstructured":"Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43:932\u20139.","journal-title":"Nat Genet"},{"key":"2723_CR73","doi-asserted-by":"publisher","first-page":"e1002200","DOI":"10.1371\/journal.pmed.1002200","volume":"13","author":"Y Li","year":"2016","unstructured":"Li Y, Buijs-Gladdines JG, Cant\u00e9-Barrett K, Stubbs AP, Vroegindeweij EM, Smits WK, et al. IL-7 Receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. PLoS Med. 2016;13:e1002200.","journal-title":"PLoS Med"},{"key":"2723_CR74","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood.2019000553","volume":"138","author":"A Silva","year":"2021","unstructured":"Silva A, Almeida ARM, Cachucho A, Neto JL, Demeyer S, de Matos M, et al. Overexpression of wild-type IL-7R\u03b1 promotes T-cell acute lymphoblastic leukemia\/lymphoma. Blood. 2021;138:1040\u201352.","journal-title":"Blood"},{"key":"2723_CR75","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2023-186699","volume":"142","author":"L Courtois","year":"2023","unstructured":"Courtois L, Cabannes-Hamy A, Kim R, Delecourt M, Pinton A, Charbonnier G, et al. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition. Blood. 2023;142:158\u201371.","journal-title":"Blood"},{"key":"2723_CR76","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/0008-5472.CAN-10-3606","volume":"71","author":"A Silva","year":"2011","unstructured":"Silva A, Laranjeira AB, Martins LR, Cardoso BA, Demengeot J, Yunes JA, et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 2011;71:4780\u20139.","journal-title":"Cancer Res"},{"key":"2723_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.3","volume":"7","author":"P Richter-Pecha\u0144ska","year":"2017","unstructured":"Richter-Pecha\u0144ska P, Kunz JB, Hof J, Zimmermann M, Rausch T, Bandapalli OR, et al. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J. 2017;7:e523.","journal-title":"Blood Cancer J"},{"key":"2723_CR78","doi-asserted-by":"crossref","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Molecular Cancer. 2019;18:26.","DOI":"10.1186\/s12943-019-0954-x"},{"key":"2723_CR79","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","volume":"23","author":"Y Pikman","year":"2017","unstructured":"Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee ES, et al. Synergistic Drug Combinations with a CDK4\/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017;23:1012\u201324.","journal-title":"Clin Cancer Res"},{"key":"2723_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30609","volume":"70","author":"EA Raetz","year":"2023","unstructured":"Raetz EA, Teachey DT, Minard C, Liu X, Norris RE, Denic KZ, et al. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: A Children\u2019s Oncology Group study (AINV18P1). Pediatr Blood Cancer. 2023;70:e30609.","journal-title":"Pediatr Blood Cancer"},{"key":"2723_CR81","doi-asserted-by":"crossref","unstructured":"Matthijssens F, Sharma ND, Nysus M, Nickl CK, Kang H, Perez DR, et al. RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. J Clin Invest. 2021;131.","DOI":"10.1172\/JCI141566"},{"key":"2723_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08049-8","volume":"12","author":"K Hlozkova","year":"2022","unstructured":"Hlozkova K, Hermanova I, Safrhansova L, Alquezar-Artieda N, Kuzilkova D, Vavrova A, et al. PTEN\/PI3K\/Akt pathway alters sensitivity of T-cell acute lymphoblastic leukemia to L-asparaginase. Sci Rep. 2022;12:4043.","journal-title":"Sci Rep"},{"key":"2723_CR83","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/nm.3955","volume":"21","author":"D Herranz","year":"2015","unstructured":"Herranz D, Ambesi-Impiombato A, Sudderth J, S\u00e1nchez-Mart\u00edn M, Belver L, Tosello V, et al. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat Med. 2015;21:1182\u20139.","journal-title":"Nat Med"},{"key":"2723_CR84","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","volume":"36","author":"LN Toksvang","year":"2022","unstructured":"Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. 2022;36:1749\u201358.","journal-title":"Leukemia"},{"key":"2723_CR85","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ccell.2019.03.004","volume":"35","author":"L Hinze","year":"2019","unstructured":"Hinze L, Pfirrmann M, Karim S, Degar J, McGuckin C, Vinjamur D, et al. Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell. 2019;35:664\u201376.e7.","journal-title":"Cancer Cell"},{"key":"2723_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1070069","volume":"13","author":"R Zhou","year":"2023","unstructured":"Zhou R, Liang T, Li T, Huang J, Chen C. Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia. Front Oncol. 2023;13:1070069.","journal-title":"Front Oncol"},{"key":"2723_CR87","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41375-020-0845-6","volume":"35","author":"JC Garc\u00eda-Ca\u00f1averas","year":"2021","unstructured":"Garc\u00eda-Ca\u00f1averas JC, Lancho O, Ducker GS, Ghergurovich JM, Xu X, da Silva-Diz V, et al. SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. Leukemia. 2021;35:377\u201388.","journal-title":"Leukemia"},{"key":"2723_CR88","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41375-021-01361-8","volume":"36","author":"Y Pikman","year":"2022","unstructured":"Pikman Y, Ocasio-Martinez N, Alexe G, Dimitrov B, Kitara S, Diehl FF, et al. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia. 2022;36:348\u201360.","journal-title":"Leukemia"},{"key":"2723_CR89","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1038\/onc.2017.59","volume":"36","author":"H Takahashi","year":"2017","unstructured":"Takahashi H, Inoue J, Sakaguchi K, Takagi M, Mizutani S, Inazawa J. Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells. Oncogene. 2017;36:4267\u201376.","journal-title":"Oncogene"},{"key":"2723_CR90","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature19801","volume":"538","author":"ED Hawkins","year":"2016","unstructured":"Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, et al. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature. 2016;538:518\u201322.","journal-title":"Nature"},{"key":"2723_CR91","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/s41375-018-0127-8","volume":"32","author":"J De Bie","year":"2018","unstructured":"De Bie J, Demeyer S, Alberti-Servera L, Geerdens E, Segers H, Broux M, et al. Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. Leukemia. 2018;32:1358\u201369.","journal-title":"Leukemia"},{"key":"2723_CR92","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/bloodadvances.2021004177","volume":"5","author":"A Di Grande","year":"2021","unstructured":"Di Grande A, Peirs S, Donovan PD, Van Trimpont M, Morscio J, Lintermans B, et al. The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL. Blood Adv. 2021;5:1963\u201376.","journal-title":"Blood Adv"},{"key":"2723_CR93","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.4049\/jimmunol.1801373","volume":"202","author":"L Ballesteros-Arias","year":"2019","unstructured":"Ballesteros-Arias L, Silva JG, Paiva RA, Carbonetto B, Fa\u00edsca P, Martins VC. T Cell Acute lymphoblastic leukemia as a consequence of thymus autonomy. J Immunol. 2019;202:1137\u201344.","journal-title":"J Immunol"},{"key":"2723_CR94","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ccell.2015.05.011","volume":"27","author":"CE de Bock","year":"2015","unstructured":"de Bock CE, Cools J. T-ALL: Home Is where the CXCL12 Is. Cancer Cell. 2015;27:745\u20136.","journal-title":"Cancer Cell"},{"key":"2723_CR95","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/JLB.1MR1217-496R","volume":"104","author":"KD James","year":"2018","unstructured":"James KD, Jenkinson WE, Anderson G. T-cell egress from the thymus: Should I stay or should I go?. J Leukoc Biol. 2018;104:275\u201384.","journal-title":"J Leukoc Biol"},{"key":"2723_CR96","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41590-019-0479-x","volume":"20","author":"JT Barata","year":"2019","unstructured":"Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 2019;20:1584\u201393.","journal-title":"Nat Immunol"},{"key":"2723_CR97","doi-asserted-by":"publisher","first-page":"E1016","DOI":"10.1073\/pnas.1520245113","volume":"113","author":"TA Triplett","year":"2016","unstructured":"Triplett TA, Cardenas KT, Lancaster JN, Hu Z, Selden HJ, Jasso GJ, et al. Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc Natl Acad Sci USA. 2016;113:E1016\u201325.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2723_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1677-z","volume":"15","author":"I Bartram","year":"2015","unstructured":"Bartram I, Erben U, Ortiz-Tanchez J, Blunert K, Schlee C, Neumann M, et al. Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL. BMC Cancer. 2015;15:663.","journal-title":"BMC Cancer"},{"key":"2723_CR99","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1038\/s12276-024-01335-7","volume":"56","author":"A Lyu","year":"2024","unstructured":"Lyu A, Nam SH, Humphrey RS, Horton TM, Ehrlich LIR. Cells and signals of the leukemic microenvironment that support progression of T-cell acute lymphoblastic leukemia (T-ALL). Exp Mol Med. 2024;56:2337\u201347.","journal-title":"Exp Mol Med"},{"key":"2723_CR100","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1038\/s41375-022-01714-x","volume":"36","author":"M Thastrup","year":"2022","unstructured":"Thastrup M, Duguid A, Mirian C, Schmiegelow K, Halsey C. Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions. Leukemia. 2022;36:2751\u201368.","journal-title":"Leukemia"},{"key":"2723_CR101","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1200\/JCO.2012.48.2315","volume":"31","author":"KR Krull","year":"2013","unstructured":"Krull KR, Brinkman TM, Li C, Armstrong GT, Ness KK, Srivastava DK, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31:4407\u201315.","journal-title":"J Clin Oncol"},{"key":"2723_CR102","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1182\/blood.2022018653","volume":"141","author":"NP Gossai","year":"2023","unstructured":"Gossai NP, Devidas M, Chen Z, Wood BL, Zweidler-McKay PA, Rabin KR, et al. Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children\u2019s Oncology Group report. Blood. 2023;141:1802\u201311.","journal-title":"Blood"},{"key":"2723_CR103","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41375-019-0570-1","volume":"34","author":"M Thastrup","year":"2020","unstructured":"Thastrup M, Marquart HV, Levinsen M, Grell K, Abrahamsson J, Albertsen BK, et al. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. Leukemia. 2020;34:336\u201346.","journal-title":"Leukemia"},{"key":"2723_CR104","doi-asserted-by":"publisher","first-page":"7231","DOI":"10.1182\/bloodadvances.2023011267","volume":"7","author":"D O\u2019Connor","year":"2023","unstructured":"O\u2019Connor D, Joy M, Enshaei A, Kirkwood A, Kearns PR, Samarasinghe S, et al. Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL. Blood Adv. 2023;7:7231\u20134.","journal-title":"Blood Adv"},{"key":"2723_CR105","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children\u2019s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38:3282\u201393.","journal-title":"J Clin Oncol"},{"key":"2723_CR106","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","volume":"8","author":"S Shimony","year":"2024","unstructured":"Shimony S, DeAngelo DJ, Luskin MR. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2024;8:23\u201336.","journal-title":"Blood Adv"},{"key":"2723_CR107","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321\u201334.","journal-title":"Blood"},{"key":"2723_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1144414","volume":"14","author":"R Velasco","year":"2023","unstructured":"Velasco R, Mussetti A, Villagr\u00e1n-Garc\u00eda M, Sureda A. CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?. Front Neurol. 2023;14:1144414.","journal-title":"Front Neurol"},{"key":"2723_CR109","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","volume":"375","author":"S Maury","year":"2016","unstructured":"Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-Lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044\u201353.","journal-title":"N Engl J Med"},{"key":"2723_CR110","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"2723_CR111","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983\u201392.","journal-title":"Blood"},{"key":"2723_CR112","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1182\/bloodadvances.2020002502","volume":"4","author":"S Leong","year":"2020","unstructured":"Leong S, Inglott S, Papaleonidopoulou F, Orfinada K, Ancliff P, Bartram J, et al. CD1a is rarely expressed in pediatric or adult relapsed\/refractory T-ALL: implications for immunotherapy. Blood Adv. 2020;4:4665\u20138.","journal-title":"Blood Adv"},{"key":"2723_CR113","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","volume":"30","author":"BLZ Oh","year":"2024","unstructured":"Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat Med. 2024;30:3687\u201396.","journal-title":"Nat Med"},{"key":"2723_CR114","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2023;389:899\u2013910.","journal-title":"N Engl J Med"},{"key":"2723_CR115","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D S\u00e1nchez-Mart\u00ednez","year":"2019","unstructured":"S\u00e1nchez-Mart\u00ednez D, Baroni ML, Gutierrez-Ag\u00fcera F, Roca-Ho H, Blanch-Lombarte O, Gonz\u00e1lez-Garc\u00eda S, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019;133:2291\u2013304.","journal-title":"Blood"},{"key":"2723_CR116","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood.2021013648","volume":"140","author":"PM Maciocia","year":"2022","unstructured":"Maciocia PM, Wawrzyniecka PA, Maciocia NC, Burley A, Karpanasamy T, Devereaux S, et al. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood. 2022;140:25\u201337.","journal-title":"Blood"},{"key":"2723_CR117","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-025-01715-0","volume":"18","author":"N Tirado","year":"2025","unstructured":"Tirado N, Fidyt K, Mansilla MJ, Garcia-Perez A, Mart\u00ednez-Moreno A, Vinyoles M, et al. CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. J Hematol Oncol. 2025;18:69.","journal-title":"J Hematol Oncol"},{"key":"2723_CR118","doi-asserted-by":"crossref","unstructured":"Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat Med. 2024;126\u201336.","DOI":"10.1038\/s41591-024-03282-2"},{"key":"2723_CR119","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131:995\u20139.","journal-title":"Blood"},{"key":"2723_CR120","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puy\u00f3 P, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144:2237\u201347.","journal-title":"Blood"},{"key":"2723_CR121","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41375-019-0434-8","volume":"33","author":"P Akkapeddi","year":"2019","unstructured":"Akkapeddi P, Fragoso R, Hixon JA, Ramalho AS, Oliveira ML, Carvalho T, et al. A fully human anti-IL-7R\u03b1 antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. Leukemia. 2019;33:2155\u201368.","journal-title":"Leukemia"},{"key":"2723_CR122","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41375-019-0531-8","volume":"34","author":"JA Hixon","year":"2020","unstructured":"Hixon JA, Andrews C, Kashi L, Kohnhorst CL, Senkevitch E, Czarra K, et al. New anti-IL-7R\u03b1 monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models. Leukemia. 2020;34:35\u201349.","journal-title":"Leukemia"},{"key":"2723_CR123","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood.2023021088","volume":"143","author":"L Lenk","year":"2024","unstructured":"Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, et al. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood. 2024;143:2735\u201348.","journal-title":"Blood"},{"key":"2723_CR124","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1182\/blood.2023020490","volume":"143","author":"J Zhang","year":"2024","unstructured":"Zhang J, Duan Y, Wu P, Chang Y, Wang Y, Hu T, et al. Clonal evolution dissection reveals that a high MSI2 level promotes chemoresistance in T-cell acute lymphoblastic leukemia. Blood. 2024;143:320\u201335.","journal-title":"Blood"},{"key":"2723_CR125","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/2159-8290.CD-21-0145","volume":"11","author":"LE Montefiori","year":"2021","unstructured":"Montefiori LE, Bendig S, Gu Z, Chen X, P\u00f6l\u00f6nen P, Ma X, et al. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discov. 2021;11:2846\u201367.","journal-title":"Cancer Discov"},{"key":"2723_CR126","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(19)32998-8","volume":"395","author":"OJ Skrede","year":"2020","unstructured":"Skrede OJ, De Raedt S, Kleppe A, Hveem TS, Liest\u00f8l K, Maddison J, et al. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet. 2020;395:350\u201360.","journal-title":"Lancet"},{"key":"2723_CR127","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583\u20139.","journal-title":"Nature"},{"key":"2723_CR128","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41746-018-0029-1","volume":"1","author":"A Rajkomar","year":"2018","unstructured":"Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, et al. Scalable and accurate deep learning with electronic health records. NPJ Digit Med. 2018;1:18.","journal-title":"NPJ Digit Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02723-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02723-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02723-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:03:30Z","timestamp":1762337010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02723-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":128,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2723"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02723-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LKX is an employee of AstraZeneca Pharmaceuticals. The other authors have no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}